Advanced Solid Tumors, Excluding T Cell Lymphoma
Conditions
Brief summary
The study is aimed to evaluate the efficacy and safety of Apatinib and MASCT in patients with advanced solid tumors.
Detailed description
Angiogenesis is a hallmark of cancer, together with vascular endothelial growth factor (VEGF) as one of the most important angiogenic drivers. Inhibitors targeting the VEGF/VEGFR-pathway have shown beneficial effects in many cancer patients, but they are transient and followed by fast regrowth. Similarly, the effectiveness of tumor immunotherapies has been limited by tumor-mediated escape mechanisms and immune suppression. By combining the two strategies, antiangiogenic immunotherapy offers the possibility to more vigorously inhibit tumor angiogenesis and promote an enduring immune-stimulatory milieu that leads to prolonged survival benefits in cancer patients. Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular endothelial growth factor receptor 2 (VEGFR-2). Apatinib has been demonstrated as monotherapy prolongs OS in patients with gastric or gastroesophageal junction adenocarcinoma after two or more lines of chemotherapy with moderate, reversible, and easily managed adverse events. Multiple antigens specific cellular therapy (MASCT) is a new immunotherapy that dendritic cells(DC) was induced from autologous peripheral blood. The DC can then be loaded with 17 antigens and re-infused. In vitro, antigen-pulsed DC can stimulate autologous T-cell proliferation and induction of autologous specific cytotoxic T-cells(CTL)，similarly re-infused. The previous research data showed that MASCT had the modest overall response and less adverse effects for Hepatocellular Carcinoma patients. The study is aimed to evaluate the efficacy and safety of Apatinib and MASCT in patients with advanced solid tumors.
Interventions
DRUGApatinib
Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
BIOLOGICALMASCT
Dendritic cells(DC) loaded with 17 antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
Sponsors
Hengrui Yuanzheng Bio-Technology Co., Ltd.
The First People's Hospital of Lianyungang
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with histologically-confirmed, advanced (unresectable) solid tumors who have progressed on standard therapy. 2. With written informed consent signed voluntarily by patients themselves. 3. The time of between Patients enrollment and the end of other anti-tumors therapies≤1 month 4. Eastern Cooperative Oncology Group Performance Status (ECOG P.S.) of ≤ 2 5. At least one measurable lesion as defined by RECIST criteria 1.1 for solid tumors. 6. Life expectancy ≥6 months. 7. With normal cardiopulmonary function. 8. Patients have adequate organ function as defined by the following criteria: * Hemoglobin (HGB) ≥85g/L * Absolute neutrophil count (ANC) ≥1.0×109/L * White blood cell (WBC) ≥3.0×109/L * Platelet count ≥50×109/L * Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) of ≤2.5 upper normal limitation (UNL) or ≤5 UNL in case of liver metastasis * Alkaline phosphatase (ALP)≤2.5 UNL * Total bilirubin (TBil) of ≤1.5 UNL * Blood urea nitrogen (BUN) and Creatinine (Cr) of≤1.5 UNL * Albumin (ALB) ≥30g/L
Exclusion criteria
1. Pregnant or expecting to pregnant 2. Participated in other clinical trials before screening except of observational study. 3. Known allergic history of sodium citrate drugs. 4. Known history of organ transplant, including autologous bone marrow transplantation and peripheral stem cell transplantation. 5. Known active brain metastases as determined by CT or MRI evaluation. 6. The use of immunosuppressive drugs with current or 14 days before enrollment. 7. Know the period of systemic and continuous use of immunomodulatory agents (such as interferon, thymosin, traditional Chinese medicine) within 6 months. 8. Prior therapy with anti-programmed death-1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody (including any other antibody or drug specifically targeting T-cell co-stimulation). 9. Known history of primary immunodeficiency diseases. 10. Known history of tuberculosis. 11. Known active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C. 12. Patients with serious infection, hepatopathy, nephropathy, respiratory disease, cardiovascular disease or incontrollable diabetes, etc. 13. Patients have other malignant tumors within 5 years,excluding melanoma and carcinoma in situ of cervix. 14. Treatment with any anti-tumors agent within 28days of first administration of study treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of treatment-related adverse events | up to 2 years | The incidence of treatment-related adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | From enrollment to progression of disease. Estimated about 6 months. | The length of time from enrollment until the time of progression of disease (PFS, progression-free survival) |
| Overall Survival (OS) | From enrollment to death of patients. Estimated about 1 year. | The length of time from enrollment until the time of death (OS, overall survival) |
| Objective Response Rate (ORR) | up to 2 years | clinical response of treatment according to RESIST v1.1 criteria (ORR, objective response rate) |
| Disease Control Rate (DCR) | up to 2 years | Disease control rate is defined as the number of patients with a best overall response of complete response (CR), partial response (PR), or stable disease (SD) based on RESIST v1.1 criteria. |
Countries
China
Contacts
Primary ContactXiaodong Jiang, Doctor
Backup ContactKaiyuan Hui, Doctor
Outcome results
None listed